Innovation

A large-scale, longitudinal study from DaVita Clinical Research presented at ASN Kidney Week bridges a vital clinical trial gap, examining GLP-1 use and clinical outcomes in home dialysis. Key Takeaways Closing a critical evidence gap: While major clinical trials have previously excluded individuals requiring dialysis, this study of 5,900 DaVita patients provides real-world data supporting […]

As DaVita expands access to Expanded hemodialysis (HD), some patients who have recently started the treatment have shared positive personal experiences, including changes in how they feel day to day. These individual stories reflect patients’ perspectives and experiences and should not be interpreted as evidence of clinical outcomes for all patients. Real-World Patient Experiences The […]

DaVita will also continue hemodiafiltration (HDF) pilots to advance a comprehensive approach to middle molecule clearance. In the ongoing pursuit of improved outcomes in kidney care, few targets have been as stubborn as the middle molecule gap. When middle molecules — larger uremic toxins that are not effectively cleared during standard high-flux dialysis — accumulate, […]

New data from the MOTheR trial1, one of the most rigorous head-to-head studies of advanced dialysis therapies to date, marks an important step forward in how the kidney care community approaches treatment for patients with end stage kidney disease. Presented at the European Renal Association (ERA) Congress in June 2026, the prospective randomized controlled trial […]

As artificial intelligence (AI) continues to take hold across all industries, Adam Weinstein, MD, chief medical information officer for DaVita, highlights how new technological capabilities also help make the human connection more central to healthcare. Recently, a New York Times article explored the question of whether advancements to AI in medicine could reduce the value […]